Log in to search using one of your social media accounts:

 

Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
CONCLUSION: Substantial clinical heterogeneity is observed within G2 and G3 GEP-NENs. The WHO 2010 classification can be improved by including the additive effect of histological differentiation and the proliferation index. IMPLICATIONS FOR PRACTICE: Gastroenteropancreatic neuroendocrine neoplasms are tumors of widely variable clinical behavior, roughly stratified by the World Health Organization (WHO) 2010 classification into three subgroups based on proliferation index. Real-world data from 2,813 patients of the Spanish Registry RGETNE demonstrated substantial clinical heterogeneity within grade (G) 2 and G3 neuroen...
Source: The Oncologist - January 12, 2018 Category: Cancer & Oncology Authors: Nuñez-Valdovinos B, Carmona-Bayonas A, Jimenez-Fonseca P, Capdevila J, Castaño-Pascual Á, Benavent M, Pi Barrio JJ, Teule A, Alonso V, Custodio A, Marazuela M, Segura Á, Beguiristain A, Llanos M, Martinez Del Prado MP, Diaz-Perez JA, Castellano D, Sev Tags: Oncologist Source Type: research

Cognitive Computing to Guide Molecular-Based Therapy Selection: Steps Forward amid Abundant Need.
PMID: 29330209 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - January 12, 2018 Category: Cancer & Oncology Authors: Ellisen LW Tags: Oncologist Source Type: research

Trastuzumab Plus Pertuzumab Resistance Does Not Preclude Response to Lapatinib Plus Trastuzumab in HER2-Amplified Colorectal Cancer.
Abstract Human epidermal growth factor 2 (HER2) amplification represents a distinct molecular subgroup of colorectal cancers that is associated with anti-epidermal growth factor receptor resistance and sensitivity to dual HER2 targeting. Although clinical trials have reported activity for trastuzumab/pertuzumab and trastuzumab/lapatinib combinations, there are no reports on lapatinib plus trastuzumab activity after resistance to trastuzumab plus pertuzumab. Presented are three cases of HER2 amplified colorectal cancer that developed acquired refractoriness to trastuzumab pertuzumab with subsequent clinical benefit...
Source: The Oncologist - January 12, 2018 Category: Cancer & Oncology Authors: Fakih MG Tags: Oncologist Source Type: research

Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis.
CONCLUSION: Olanzapine-based triplet stood out in terms of nausea control and drug price but represented no significant difference of CRs in comparison with NK-1RAs-based triplet. Olanzapine-based triple regimens should be an optional antiemetic choice for patients with HEC, especially those suffering from delayed phase nausea. IMPLICATIONS FOR PRACTICE: According to the results of this study, olanzapine-based triple antiemetic regimens were superior in both overall and delayed-phase nausea control when compared with various neurokinin-1 receptor antagonists-based triple regimens in patients with highly emetogenic che...
Source: The Oncologist - January 12, 2018 Category: Cancer & Oncology Authors: Zhang Z, Zhang Y, Chen G, Hong S, Yang Y, Fang W, Luo F, Chen X, Ma Y, Zhao Y, Zhan J, Xue C, Hou X, Zhou T, Ma S, Gao F, Huang Y, Chen L, Zhou N, Zhao H, Zhang L Tags: Oncologist Source Type: research

Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
CONCLUSION: In this contemporary, population-based study of women with MBC, HER2 but not HR status was associated with improved survival. Survival was similar between HER2 positive MBC and HER2 positive IDC. This suggests HER2 positive MBC is responsive to HER2-directed therapy, a finding that may offer insights for additional therapeutic approaches to MBC. IMPLICATIONS FOR PRACTICE: This population-based study reports recent outcomes, by receptor status, for women with metaplastic breast cancer. Survival in metaplastic breast cancer is not impacted by hormone receptor status. To the authors' knowledge, this is the fi...
Source: The Oncologist - January 12, 2018 Category: Cancer & Oncology Authors: Schroeder MC, Rastogi P, Geyer CE, Miller LD, Thomas A Tags: Oncologist Source Type: research

Fertility-Sparing Treatment of Endometrial Cancer with Initial Infiltration of Myometrium by Resectoscopic Surgery: A Pilot Study.
Abstract Three women with a well-differentiated grade 1 endometrioid adenocarcinoma of the endometrium with minimal myometrial infiltration were treated with hysteroscopic resection and hormone therapy. The presence of myometrial infiltration has often been mentioned as an exclusion criterion for conservative management in young patients because of worsening cancer prognosis. The subsequent 5-year follow-up and the pregnancies achieved may confirm the choice of this temporary treatment and indicate a new option for fertility-sparing treatment in highly motivated patients. PMID: 29317550 [PubMed - as supplied ...
Source: The Oncologist - January 9, 2018 Category: Cancer & Oncology Authors: Casadio P, Guasina F, Paradisi R, Leggieri C, Caprara G, Seracchioli R Tags: Oncologist Source Type: research

Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.
CONCLUSION: During the year following U.S. regulatory approval of PD-1 inhibitors for treatment of NSCLC, real-world patients receiving nivolumab or pembrolizumab were older at treatment initiation and more had smoking history relative to clinical trial cohorts. Studies of outcomes in underrepresented subgroups are needed to inform real-world treatment decisions. IMPLICATIONS FOR PRACTICE: Evidence gathered in conventional clinical trials used to assess safety and efficacy of new therapies is not necessarily generalizable to real-world patients receiving these drugs following regulatory approval. Real-world evidence d...
Source: The Oncologist - January 9, 2018 Category: Cancer & Oncology Authors: Khozin S, Abernethy AP, Nussbaum NC, Zhi J, Curtis MD, Tucker M, Lee SE, Light DE, Gossai A, Sorg RA, Torres AZ, Patel P, Blumenthal GM, Pazdur R Tags: Oncologist Source Type: research

Validation and Refinement of the Age, Comorbidities, and Albumin Index in Elderly Patients with Diffuse Large B-Cell Lymphoma: An Effective Tool for Comprehensive Geriatric Assessment.
CONCLUSION: We observed that the ACA index could partially predict the clinical outcomes of elderly DLBCL patients in China. Based on this index, we proposed the IACA index as an effective tool for CGA in DLBCL. IMPLICATIONS FOR PRACTICE: Diffuse large B-cell lymphoma (DLBCL) is one of the most frequent types of malignant lymphoma in elderly people, and identifying patients suitable for curative therapy is critical in the improvement of clinical outcomes. Recently, some authors proposed the Age, Comorbidities, and Albumin (ACA) index. Combining the use of the instrumental activities of daily living (IADL) scale and th...
Source: The Oncologist - January 9, 2018 Category: Cancer & Oncology Authors: Liu H, Zhang CL, Feng R, Li JT, Tian Y, Wang T Tags: Oncologist Source Type: research

Safety Profile of Biosimilar Filgrastim (Zarzio/Zarxio): A Combined Analysis of Phase III Studies.
ell K Abstract BACKGROUND: Evaluation of adverse events (AEs) in pivotal registration trials and ongoing postmarketing surveillance is important for all biologics, including biosimilars. A combined analysis of two pivotal registration studies was performed to strengthen evidence on safety for biosimilar filgrastim EP2006 in patients with breast cancer receiving myelosuppressive chemotherapy, a sensitive clinical setting to confirm biosimilarity of filgrastim. MATERIALS AND METHODS: Data were combined from two phase III studies of biosimilar filgrastim EP2006. The U.S. registration study was a randomized, doub...
Source: The Oncologist - January 9, 2018 Category: Cancer & Oncology Authors: Harbeck N, Gascón P, Krendyukov A, Hoebel N, Gattu S, Blackwell K Tags: Oncologist Source Type: research

Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.
CONCLUSION: R-B as a first-line treatment of FL3A is better tolerated than R-CHOP and seems to induce more profound responses, leading to a significantly lower relapse rate and prolonged PFS. Therefore, R-B is a valid treatment option for FL grade 3A. IMPLICATIONS FOR PRACTICE: Rituximab plus bendamustine (R-B) has shown to be less toxic and more effective than rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHOP) in follicular lymphoma grade 3A. Although both regimens can induce a complete remission in>95% of patients, relapses occur more frequently after R-CHOP than R-B, leading to a significantly lon...
Source: The Oncologist - January 9, 2018 Category: Cancer & Oncology Authors: Mondello P, Steiner N, Willenbacher W, Cerchione C, Nappi D, Mauro E, Ferrero S, Cuzzocrea S, Mian M Tags: Oncologist Source Type: research

Appendiceal Mucinous Neoplasms: Diagnosis and Management
(Source: The Oncologist)
Source: The Oncologist - January 9, 2018 Category: Cancer & Oncology Authors: Walid L. Shaib, Rita Assi, Ali Shamseddine, Olatunȷi B. Alese, Charles Staley III, Bahar Memis, Volkan Adsay, Tanios Bekaii-Saab, Bassel F. El-Rayes Tags: Erratum Source Type: research

In Reply
(Source: The Oncologist)
Source: The Oncologist - January 9, 2018 Category: Cancer & Oncology Authors: Richard M. Goldberg, Lai Wei, Soledad Fernandez Tags: Letters to the Editor Source Type: research

Clinical Trials in Oncology and Defining Benefit
(Source: The Oncologist)
Source: The Oncologist - January 9, 2018 Category: Cancer & Oncology Authors: Steven Sorscher Tags: Letters to the Editor Source Type: research

Impact of Metastasectomy in the Multimodality Approach for BRAF V600E Metastatic Colorectal Cancer: The Mayo Clinic Experience
Conclusion.Multimodality therapy incorporating metastasectomy for BRAF V600E mCRC should be considered and might be associated with improved overall survival in select patients.Implications for Practice.BRAF V600E metastatic colorectal cancer (mCRC) represents an extremely difficult molecular subset of colorectal cancer to treat. To date, this subset remains refractory to standard chemotherapies, prompting extensive clinical investigation regarding novel treatment approaches and targeted modalities. While the use of metastasectomy for expanded RAS wild‐type and RAS mutated mCRC has resulted in improved overall survival f...
Source: The Oncologist - January 9, 2018 Category: Cancer & Oncology Authors: Benny Johnson, Zhaohui Jin, Mark J. Truty, Rory L. Smoot, David M. Nagorney, Michael L. Kendrick, Benjamin R. Kipp, Axel Grothey Tags: Gastrointestinal Cancer Source Type: research

Improved Detection of Circulating Epithelial Cells in Patients with Intraductal Papillary Mucinous Neoplasms
Conclusion.Our findings increase the sensitivity of detection of these cells and therefore could have clinical implications for cancer risk stratification.Implications for Practice.This work describes a high‐sensitivity platform for detection of epithelial cells shed from preneoplastic lesions at high risk of malignant transformation. Further research efforts are underway to define the transcriptional programs that might allow discrimination between circulating cells released from tumors that will become malignant and cells released from tumors that will not. After further refinement, this combination of technologies cou...
Source: The Oncologist - January 9, 2018 Category: Cancer & Oncology Authors: Joseph W. Franses, Omer Basar, Abdurrahman Kadayifci, Osman Yuksel, Melissa Choz, Anupriya S. Kulkarni, Eric Tai, Kevin D. Vo, Kshitij S. Arora, Niyati Desai, Joseph A. Licausi, Mehmet Toner, Shyamala Maheswaran, Daniel A. Haber, David P. Ryan, William R. Tags: Cancer Diagnostics and Molecular Pathology, Gastrointestinal Cancer Source Type: research

Anti‐Hu‐Associated Autoimmune Limbic Encephalitis in a Patient with PD‐1 Inhibitor‐Responsive Myxoid Chondrosarcoma
This article reports a case of fatal anti‐Hu‐associated autoimmune limbic encephalitis presenting within 8 weeks following anti‐PD1 therapy in a patient with myxoid chondrosarcoma and pre‐existing anti‐Hu antibodies. Although tumor reduction occurred in response to PD‐1 inhibitor therapy, the patient had a rapidly progressive decline in neurologic function despite initial stabilization with immunosuppression. Considering the increasing use of immune checkpoint inhibitors for the treatment of various malignancies, an increase in the occurrence of neurologic adverse events is likely, requiring prompt intervention...
Source: The Oncologist - January 9, 2018 Category: Cancer & Oncology Authors: Kyriakos P. Papadopoulos, Rebecca S. Romero, Gabriela Gonzalez, James E. Dix, Israel Lowy, Matthew Fury Tags: Symptom Management and Supportive Care Brief Communications Source Type: research

Cancer Immunotherapy Trials Underutilize Immune Response Monitoring
We report the results from a cross‐sectional analysis of response monitoring in 685 T‐cell checkpoint‐targeted cancer immunotherapy trials in solid malignancies, as registered on the U.S. National Institutes of Health trial registry by October 2016. Immune‐related radiological response criteria were registered for only 25% of clinical trials. Only 38% of trials registered an exploratory immunological biomarker, and registration of immunological biomarkers has decreased over the last 15 years. We suggest that increasing the utilization of immune‐related response monitoring across cancer immunotherapy trials will i...
Source: The Oncologist - January 9, 2018 Category: Cancer & Oncology Authors: Claire M. Connell, Sophie E.M. Raby, Ian Beh, Thomas R. Flint, Edward H. Williams, Douglas T. Fearon, Duncan I. Jodrell, Tobias Janowitz Tags: New Drug Development and Clinical Pharmacology, Precision Medicine Brief Communications Source Type: research

Effectiveness of Oncologist‐Referred Exercise and Healthy Eating Programming as a Part of Supportive Adjuvant Care for Early Breast Cancer
AbstractBackground.Randomized trials have established efficacy of supervised exercise training during chemotherapy for breast cancer for numerous health outcomes. The purpose of this study was to assess reach, effectiveness, maintenance, and implementation of an evidence‐based exercise and healthy eating program offered within an adjuvant care setting.Subjects, Materials, and Methods.Women receiving adjuvant chemotherapy for breast cancer were given a prescription by their oncologist to participate in the Nutrition and Exercise during Adjuvant Treatment (NExT) program. The NExT program consisted of supervised, moderate...
Source: The Oncologist - January 9, 2018 Category: Cancer & Oncology Authors: Amy A. Kirkham, Cheri L. Van Patten, Karen A. Gelmon, Donald C. McKenzie, Alis Bonsignore, Kelcey A. Bland, Kristin L. Campbell Tags: Symptom Management and Supportive Care, Breast Cancer Source Type: research

Sarcopenia Is Associated with Quality of Life and Depression in Patients with Advanced Cancer
AbstractBackground.Patients with advanced cancer often experience muscle wasting (sarcopenia), yet little is known about the characteristics associated with sarcopenia and the relationship between sarcopenia and patients’ quality of life (QOL) and mood.Materials and Methods.As part of a randomized trial, we assessed baseline QOL (Functional Assessment of Cancer Therapy‐General [FACT‐G]) and mood (Hospital Anxiety and Depression Scale [HADS]) in patients within 8 weeks of diagnosis of incurable lung or gastrointestinal cancer, and prior to randomization. Using computed tomography scans collected as part of routine...
Source: The Oncologist - January 9, 2018 Category: Cancer & Oncology Authors: Ryan D. Nipp, Georg Fuchs, Areeȷ El-Jawahri, Julia Mario, Fabian M. Troschel, Joseph A. Greer, Emily R. Gallagher, Vicki A. Jackson, Avinash Kambadakone, Theodore S. Hong, Jennifer S. Temel, Florian J. Fintelmann Tags: Symptom Management and Supportive Care Source Type: research

A Clinical and Biological Guide for Understanding Chemotherapy‐Induced Alopecia and Its Prevention
AbstractChemotherapy‐induced alopecia (CIA) is the most visibly distressing side effect of commonly administered chemotherapeutic agents. Because psychological health has huge relevance to lifestyle, diet, and self‐esteem, it is important for clinicians to fully appreciate the psychological burden that CIA can place on patients. Here, for the first time to our knowledge, we provide a comprehensive review encompassing the molecular characteristics of the human hair follicle (HF), how different anticancer agents damage the HF to cause CIA, and subsequent HF pathophysiology, and we assess known and emerging prevention mod...
Source: The Oncologist - January 9, 2018 Category: Cancer & Oncology Authors: Christopher John Dunnill, Wafaa Al-Tameemi, Andrew Collett, Iain Stuart Haslam, Nikolaos Theodoros Georgopoulos Tags: Review, Symptom Management and Supportive Care Source Type: research

Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas
This article reviews the history of and current state of immunotherapy research in the treatment of soft tissue and bone sarcomas, with particular regard to vaccine trials, adoptive T‐cell therapy, and immune checkpoint blockade. (Source: The Oncologist)
Source: The Oncologist - January 9, 2018 Category: Cancer & Oncology Authors: Michael J. Nathenson, Anthony P. Conley, Edward Sausville Tags: Review, Sarcomas Source Type: research

Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma
Conclusion.The value of pazopanib in advanced ASPS is confirmed, with durable responses, whereas the value of trabectedin appears limited. These results are relevant to defining the best approach to advanced ASPS.Implications for Practice.This retrospective study, conducted among the world reference centers for treatment of sarcoma, confirms the value of pazopanib in patients with advanced alveolar soft part sarcoma (ASPS), with dimensional and durable responses, whereas trabectedin shows a limited activity. Alveolar soft part sarcoma is resistant to conventional cytotoxic chemotherapy. Pazopanib and trabectedin are licens...
Source: The Oncologist - January 9, 2018 Category: Cancer & Oncology Authors: Silvia Stacchiotti, Olivier Mir, Axel Le Cesne, Bruno Vincenzi, Alexander Fedenko, Robert G. Maki, Neeta Somaiah, Shreyaskumar Patel, Mehedi Brahmi, Jean Y. Blay, Kȷetil Boye, Kirsten Sundby Hall, Hans Gelderblom, Nadia Hindi, Javier Martin-Broto, Tags: Sarcomas Source Type: research

Consensus Guideline for Use of Glucarpidase in Patients with High‐Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance
AbstractAcute kidney injury due to high‐dose methotrexate (HDMTX) is a serious, life‐threatening toxicity that can occur in pediatric and adult patients. Glucarpidase is a treatment approved by the Food and Drug Administration for high methotrexate concentrations in the context of kidney dysfunction, but the guidelines for when to use it are unclear. An expert panel was convened to provide specific, expert consensus guidelines for the use of glucarpidase in patients who develop HDMTX‐induced nephrotoxicity and delayed methotrexate excretion. The guideline provides recommendations to identify the population of patient...
Source: The Oncologist - January 9, 2018 Category: Cancer & Oncology Authors: Laura B. Ramsey, Frank M. Balis, Maureen M. O'Brien, Kjeld Schmiegelow, Jennifer L. Pauley, Archie Bleyer, Brigitte C. Widemann, David Askenazi, Sharon Bergeron, Anushree Shirali, Stefan Schwartz, Alexander A. Vinks, Jesper Heldrup Tags: New Drug Development and Clinical Pharmacology, Symptom Management and Supportive Care Source Type: research

Individual Trade‐Offs Between Possible Benefits and Risks of Cancer Treatments: Results from a Stated Preference Study with Patients with Multiple Myeloma
Conclusion.Stated preference studies provide a systematic approach to gain knowledge about the distribution of preferences in the population and about what this implies for patients’ acceptance of specific treatments.Implications for Practice.This study demonstrated how quantitative preference statements from a large group of participants can be collected through an online survey and how such information may be used to explore the acceptability of specific treatments based on the attributes studied. Results from such studies have the potential to become an important new tool for gathering patient views and studying h...
Source: The Oncologist - January 9, 2018 Category: Cancer & Oncology Authors: Douwe Postmus, Sarah Richard, Nathalie Bere, Gert van Valkenhoef, Jayne Galinsky, Eric Low, Isabelle Moulon, Maria Mavris, Tomas Salmonsson, Beatriz Flores, Hans Hillege, Francesco Pignatti Tags: Myelomas, Health Outcomes and Economics of Cancer Care Source Type: research

Perspectives of Screening‐Eligible Women and Male Partners on Benefits of and Barriers to Treatment for Precancerous Lesions and Cervical Cancer in Kenya
Conclusion.Incorporating qualitative data on benefits of and barriers to treatment for precancerous lesions and cervical cancer into Kenya's national priorities and activities is important. These findings can be used to inform the development and successful implementation of targeted, region‐specific community outreach and health messaging campaigns focused on alleviating the country's cervical cancer burden.Implications for Practice.This article provides important insight into female and male partner perspectives regarding benefits, facilitators, and barriers to treatment for precancerous lesions and cervical cancer. Th...
Source: The Oncologist - January 9, 2018 Category: Cancer & Oncology Authors: Kathleen R. Ragan, Natasha Buchanan Lunsford, Judith Lee Smith, Mona Saraiya, Millicent Aketch Tags: Gynecologic Oncology, Global Health and Cancer Source Type: research

A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer
AbstractThe emergence of targeted therapies for the treatment of metastatic colorectal cancer (mCRC) has considerably improved survival, but has also resulted in a dilemma of identifying the optimal sequence and combination of various agents in the mCRC treatment landscape. A number of cytotoxic agents, including irinotecan, oxaliplatin, 5‐fluorouracil, capecitabine, and TAS‐102, are available for treatment of mCRC. Additionally, whereas patients harboring rat sarcoma viral oncogene homolog (RAS)–wild type mCRC can be treated with the anti‐epidermal growth factor receptor antibodies cetuximab and panitumumab or...
Source: The Oncologist - January 9, 2018 Category: Cancer & Oncology Authors: Kristen K. Ciombor, Tanios Bekaii-Saab Tags: Precision Medicine, Gastrointestinal Cancer Source Type: research

Patient‐Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo‐Controlled, Double‐Blind and 32‐Week Open‐Label Study
Conclusion.Improved diarrhea and flushing control in CS patients during 16‐week lanreotide treatment was sustained during maintenance of lanreotide treatment for the 32‐week IOL phase (48 weeks total).Implications for Practice.This study prospectively collected daily patient‐reported data on diarrhea and flushing from the ELECT trial to evaluate the direct impact of lanreotide depot on patients’ relief of carcinoid syndrome symptoms. Treatment with lanreotide depot was associated with significant reductions in the percentages of days patients reported symptoms of diarrhea and flushing, as well as reductions in ...
Source: The Oncologist - January 9, 2018 Category: Cancer & Oncology Authors: George A. Fisher, Jr., Edward M. Wolin, Nilani Liyanage, Susan Pitman Lowenthal, Beloo Mirakhur, Rodney F. Pommier, Montaser Shaheen, Aaron Vinik, on behalf of the ELECT Study Group Tags: Symptom Management and Supportive Care, Gastrointestinal Cancer Source Type: research

Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study
This study compared the efficacy of regorafenib and trifluridine/tipiracil (TFTD) in patients with metastatic colorectal cancer (mCRC) who are refractory to standard chemotherapy, because despite their clinical approval, it still remains unclear which of these two drugs should be used as initial treatment.Materials and Methods.The clinical data of patients with mCRC who were treated with regorafenib or TFTD and those of drug‐naive patients, between June 2014 and September 2015, were retrospectively collected from 24 institutions in Japan. Overall survival (OS) was evaluated using the Cox's proportional hazard models base...
Source: The Oncologist - January 9, 2018 Category: Cancer & Oncology Authors: Toshikazu Moriwaki, Shota Fukuoka, Hiroya Taniguchi, Atsuo Takashima, Yusuke Kumekawa, Takeshi Kajiwara, Kentaro Yamazaki, Taito Esaki, Chinatsu Makiyama, Tadamichi Denda, Hironaga Satake, Takeshi Suto, Naotoshi Sugimoto, Masanobu Enomoto, Toshiaki Ishika Tags: Gastrointestinal Cancer Source Type: research

Predictors of Response and Survival in Locally Advanced Adenocarcinoma of the Pancreas Following Neoadjuvant GTX with or Without Radiation Therapy
Conclusion.R0 resection, the goal of neoadjuvant treatment, can be achieved in 70% of patients presenting with locally advanced pancreatic cancer. The median DFS was 31 months (95% CI: 11. 3–51.1). No relationship was found with tumor size, degree of vascular involvement, carcinoembryonic antigen test (CEA), CA 19‐9, degree of tumor regression on scan, fall in CA 19‐9, or SUV on PET scan and subsequent survival. (Source: The Oncologist)
Source: The Oncologist - January 9, 2018 Category: Cancer & Oncology Authors: William H. Sherman, Elizabeth Hecht, David Leung, Kyung Chu Tags: Chinese Edition, Clinical Trial Results, Endocrinology Source Type: research

Phase II Trial Using a Combination of Oxaliplatin, Capecitabine, and Celecoxib with Concurrent Radiation for Newly Diagnosed Resectable Rectal Cancer
Conclusion.Chemoradiation with celecoxib in rectal cancer was well tolerated and demonstrated high rates of pCR, SD, and SSS. Improvement in skin toxicity (34% grade 1 and no grade 3/4) as compared with historical results (43%–78% grade 3/4) seems to be a significant improvement with addition of celecoxib to neoadjuvant chemotherapy. (Source: The Oncologist)
Source: The Oncologist - January 9, 2018 Category: Cancer & Oncology Authors: Emilio P. Arauȷo-Mino, Yehuda Z. Patt, Cristina Murray-Krezan, Joshua A. Hanson, Pranshu Bansal, Ben J. Liem, Ashwani Raȷput, M. Houman Fekrazad, Glenory Heywood, Fa Chyi Lee Tags: Chinese Edition, Clinical Trial Results, Gastrointestinal Cancer Source Type: research

Adverse Event Reporting in Clinical Trials: Time to Include Duration as Well as Severity
(Source: The Oncologist)
Source: The Oncologist - January 9, 2018 Category: Cancer & Oncology Authors: Oliver Sartor Tags: New Drug Development and Clinical Pharmacology Editorial Source Type: research

Appendiceal Mucinous Neoplasms: Diagnosis and Management.
PMID: 29317549 [PubMed - in process] (Source: The Oncologist)
Source: The Oncologist - January 1, 2018 Category: Cancer & Oncology Authors: Shaib WL, Assi R, Shamseddine A, Alese OB, Staley C, Memis B, Adsay V, Bekaii-Saab T, El-Rayes BF Tags: Oncologist Source Type: research

Autologous Stem Cell Transplantation in Elderly Lymphoma Patients in Their 70s: Outcomes and Analysis.
CONCLUSION: Eligibility for ASCT should be an individualized decision, and age should not be an absolute contraindication to ASCT in healthy elderly patients with lymphoma. IMPLICATIONS FOR PRACTICE: Although high-dose chemotherapy and autologous stem cell transplantation (ASCT) can offer durable remission in many patients with relapsed or high-risk lymphoma, elderly patients are often not considered candidates due to concern for excess toxicity and mortality. This retrospective study showed favorable transplant outcomes, including survival and toxicity, in a large cohort of lymphoma patients over 70 years of age who ...
Source: The Oncologist - December 28, 2017 Category: Cancer & Oncology Authors: Sun L, Li S, El-Jawahri A, Armand P, Dey BR, Fisher DC, Jacobsen ED, Jacobson CA, LaCasce AS, McAfee SL, Spitzer TR, Chen YB, DeFilipp Z Tags: Oncologist Source Type: research

Barriers and Explanatory Mechanisms of Delays in the Patient and Diagnosis Intervals of Care for Breast Cancer in Mexico.
CONCLUSION: Our findings support the relevance of strengthening early cancer diagnosis strategies, especially the improvement of quality of primary care and expedited referral routes to cancer services. IMPLICATIONS FOR PRACTICE: This study's findings suggest that policy in low- and middle-income countries (LMICs) should be directed toward reducing delays in diagnosis, before the implementation of mammography screening programs. The results suggest several factors susceptible to early diagnosis interventions. To reduce patient delays, the usually proposed intervention of awareness promotion could better work in LMIC c...
Source: The Oncologist - December 28, 2017 Category: Cancer & Oncology Authors: Unger-Saldaña K, Ventosa-Santaulària D, Miranda A, Verduzco-Bustos G Tags: Oncologist Source Type: research

Portomesenteric Venous Stenting for Palliation of Ascites and Variceal Bleeding Caused by Prehepatic Portal Hypertension.
Abstract BACKGROUND: The purpose of this study was to evaluate percutaneous transhepatic portal vein stenting (PVS) for palliation of refractory ascites and/or variceal bleeding caused by extrahepatic portomesenteric venous stenosis in patients with pancreaticobiliary cancer. MATERIALS AND METHODS: A single-institution, retrospective review of patients who underwent PVS between January 2007 and July 2015 was performed. A total of 38 patients were identified, of whom 28 met the inclusion criterion of PVS performed primarily for refractory ascites or variceal bleeding. In addition to technical success and overa...
Source: The Oncologist - December 28, 2017 Category: Cancer & Oncology Authors: Sheth RA, Sabir SH, Parmet P, Amin R, Kuban JD, Huang SY, Mahvash A, Fogelman D, Javle M, Wallace MJ Tags: Oncologist Source Type: research

The Concept of Biosimilars: From Characterization to Evolution-A Narrative Review.
This article highlights the importance of biosimilars, as a cost-cutting strategy, in the delivery of state-of-the-art health care in developing countries, at a fraction of what a reference biological agent would cost. PMID: 29284760 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - December 28, 2017 Category: Cancer & Oncology Authors: Farhat F, Torres A, Park W, de Lima Lopes G, Mudad R, Ikpeazu C, Abi Aad S Tags: Oncologist Source Type: research

Refugees in Conflict: Creating a Bridge Between Traditional and Conventional Health Belief Models.
This article presents the conclusions of a workshop attended by a group of clinicians and researchers affiliated with the Middle East Cancer Consortium, as well as four European-based health-related organizations. Workshop participants included leading clinicians and medical educators from the field of integrative medicine and supportive cancer care from Italy, Germany, Turkey, Israel, Palestine, Iran, Lebanon, Jordan, Egypt, and Sudan. The workshop illustrated the need for creating a dialogue between European health care professionals and the refugee population in order to overcome the communication barriers to create hea...
Source: The Oncologist - December 28, 2017 Category: Cancer & Oncology Authors: Ben-Arye E, Bonucci M, Daher M, Kebudi R, Saad B, Breitkreuz T, Rassouli M, Rossi E, Gafer N, Nimri O, Hablas M, Kienle GS, Samuels N, Silbermann M Tags: Oncologist Source Type: research

Extreme Prostate-Specific Antigen Response to Infusional 5-Flourouracil in Castrate-Resistant Prostate Cancer.
Abstract Prostate cancer that has progressed after androgen deprivation, abiraterone, and taxane therapy is challenging to treat successfully. Herein we report a dramatic response to continuous-infusion 5-fluorouracil (5-FU) at a dose of 200 mg/m2 in a patient with rapidly progressive, heavily pretreated, metastatic castrate-resistant prostate cancer. Baseline prostate-specific antigen values declined from 1,890 ng/mL to
Source: The Oncologist - December 19, 2017 Category: Cancer & Oncology Authors: Manogue C, Ledet E, Guddati AK, Lewis B, Sartor O Tags: Oncologist Source Type: research

Racial and Ethnic Composition of Cancer Clinical Drug Trials: How Diverse Are We?
Abstract Many approved drugs demonstrate different pharmacokinetics, pharmacodynamics, and/or safety across racial and ethnic groups. The primary objective of the current study was to summarize the racial and ethnic makeup of cancer clinical drug trials using cancer drugs approved by the U.S. Food and Drug Administration (FDA) between January 1, 2010, and July 31, 2016. In clinical studies used for FDA approvals, 82.3% of participants identified as white, 10.2% as Asian, 2.3% as black, and 4.7% as Hispanic. Black participants made up 7.7% of U.S. and Canadian cancer clinical drug trials and 2.6% of global cancer c...
Source: The Oncologist - December 19, 2017 Category: Cancer & Oncology Authors: Dickmann LJ, Schutzman JL Tags: Oncologist Source Type: research

Phase II Study of Panitumumab in RAS Wild-Type Metastatic Adenocarcinoma of Small Bowel or Ampulla of Vater.
CONCLUSION: Panitumumab had no clinically meaningful activity in patients with metastatic RAS wild-type SBA and AAC. Our findings may relate to the primarily midgut and foregut derivation of the small bowel and ampulla. PMID: 29259073 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - December 19, 2017 Category: Cancer & Oncology Authors: Gulhati P, Raghav K, Shroff R, Varadhachary G, Javle M, Qiao W, Wang H, Morris J, Wolff R, Overman MJ Tags: Oncologist Source Type: research

Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions.
Abstract The emergence of immunotherapy has revolutionized cancer treatment in recent years. Inhibitors of immune checkpoints, including antibodies against cytotoxic T-lymphocyte-associated protein 4, programmed cell death protein 1, and programmed death ligand 1, have demonstrated notable efficacy in certain advanced cancers. Unfortunately, many patients do not benefit from these therapies and either exhibit primary resistance to treatment or develop acquired mechanisms of resistance after initially responding to therapy. Here, we review the genomic and immune traits that may promote resistance to T-cell-mediated...
Source: The Oncologist - December 14, 2017 Category: Cancer & Oncology Authors: Chae YK, Oh MS, Giles FJ Tags: Oncologist Source Type: research

Results of Fertility-Sparing Surgery for Expansile and Infiltrative Mucinous Ovarian Cancers.
CONCLUSION: The type of mucinous cancer has no impact on the oncologic outcome in this series of patients treated conservatively. Fertility-sparing surgery should be considered for early-stage infiltrative-type tumors. IMPLICATIONS FOR PRACTICE: According to the most recently updated World Health Organization classification guidelines, mucinous cancers should be classified as either expansile or infiltrative. The infiltrative type has a poorer prognosis, but there are no data about the safety of fertility-sparing surgery (FSS) in this context. A collection of 21 cases reviewed by two expert pathologists this study is ...
Source: The Oncologist - December 14, 2017 Category: Cancer & Oncology Authors: Gouy S, Saidani M, Maulard A, Bach-Hamba S, Bentivegna E, Leary A, Pautier P, Devouassoux-Shisheboran M, Genestie C, Morice P Tags: Oncologist Source Type: research

FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation.
Abstract On March 30, 2017, the U.S. Food and Drug Administration (FDA) approved osimertinib for the treatment of patients with metastatic, epidermal growth factor receptor (EGFR) T790M mutation-positive, non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, whose disease has progressed following EGFR tyrosine kinase inhibitor (TKI) therapy. Approval was based on demonstration of a statistically significant difference in the primary endpoint of progression-free survival (PFS) when comparing osimertinib with chemotherapy in an international, multicenter, open-label, randomized trial (AURA3). In t...
Source: The Oncologist - December 14, 2017 Category: Cancer & Oncology Authors: Odogwu L, Mathieu L, Goldberg KB, Blumenthal GM, Larkins E, Fiero MH, Rodriguez L, Bijwaard K, Lee EY, Philip R, Fan I, Donoghue M, Keegan P, McKee A, Pazdur R Tags: Oncologist Source Type: research

Patient-Reported Comorbidity and Survival in Older Adults with Cancer.
CONCLUSION: Comorbid conditions in older adults with cancer are highly prevalent and associated with all-cause mortality, particularly those conditions that impair function. Routine comorbidity assessment should be included in clinical trials and can be measured via a simple one-page patient-reported questionnaire. IMPLICATIONS FOR PRACTICE: In order to optimize and personalize the care of older adults with cancer, systematic measurement of comorbidities is necessary in both clinical trials and routine practice. Patient-reported comorbid conditions in older adults with cancer are highly prevalent and are associated wi...
Source: The Oncologist - December 14, 2017 Category: Cancer & Oncology Authors: Williams GR, Deal AM, Lund JL, Chang Y, Muss HB, Pergolotti M, Guerard EJ, Shachar SS, Wang Y, Kenzik K, Sanoff HK Tags: Oncologist Source Type: research

Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Na ïve Advanced Pancreatic Neuroendocrine Tumors.
CONCLUSION: BEZ235 treatment in mTOR inhibitor-naïve patients with advanced pNET did not demonstrate increased efficacy compared with everolimus and may be associated with a poorer tolerability profile. PMID: 29242283 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - December 14, 2017 Category: Cancer & Oncology Authors: Salazar R, Garcia-Carbonero R, Libutti SK, Hendifar AE, Custodio A, Guimbaud R, Lombard-Bohas C, Ricci S, Klümpen HJ, Capdevila J, Reed N, Walenkamp A, Grande E, Safina S, Meyer T, Kong O, Salomon H, Tavorath R, Yao JC Tags: Oncologist Source Type: research

ClinVar Is a Critical Resource to Advance Variant Interpretation
(Source: The Oncologist)
Source: The Oncologist - December 13, 2017 Category: Cancer & Oncology Authors: Heidi L. Rehm, Steven M. Harrison, Christa L. Martin Tags: Letters to the Editor Source Type: research

In Reply
(Source: The Oncologist)
Source: The Oncologist - December 13, 2017 Category: Cancer & Oncology Authors: Guillermo de Velasco, Aedin C. Culhane, Daniel Y.C. Heng, Sabina Signoretti, Toni K. Choueiri Tags: Letters to the Editor Source Type: research

The Issue of Tissue in Molecular Stratification
(Source: The Oncologist)
Source: The Oncologist - December 13, 2017 Category: Cancer & Oncology Authors: Min-Han Tan, Yukti Choudhury, Puay Hoon Tan, Quan Sing Ng, Chee Keong Toh, Ravindran Kanesvaran Tags: Letters to the Editor Source Type: research

Volume 22 Acknowledgments
(Source: The Oncologist)
Source: The Oncologist - December 13, 2017 Category: Cancer & Oncology Tags: Volume 22 Acknowledgments Source Type: research

Volume 22 Author Index
(Source: The Oncologist)
Source: The Oncologist - December 13, 2017 Category: Cancer & Oncology Tags: Volume 22 Author Index Source Type: research